NovoCure Stock Forecast

Stock Price Forecast

According to 7 analysts polled by S&P Global, NovoCure stock has a consensus rating of "Buy" and an average price target of $26. The average 1-year stock price forecast is 54.76% higher than the current stock price, while the lowest is $17 (+1.19%) and the highest is $46 (+173.81%).

Price Target: $26 (+54.76%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$17	$26	$27	$46
Change	+1.19%	+54.76%	+60.71%	+173.81%

Analyst Ratings

The average analyst rating for NovoCure stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	4	4	4	4	4	4
Buy	1	1	1	1	1	1
Hold	2	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	7	7	7	7	7

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Unknown Analyst Wedbush No rating	Wedbush	Hold Maintains $18	Hold	Maintains	$18	+7.14%	Jun 30, 2026
Emily Bodnar H.C. Wainwright	H.C. Wainwright	Buy Maintains $46	Buy	Maintains	$46	+173.81%	Jun 22, 2026
Jason Bednar Piper Sandler	Piper Sandler	Buy Maintains $27	Buy	Maintains	$27	+60.71%	May 26, 2026
Larry Biegelsen Wells Fargo	Wells Fargo	Hold Reiterates $14 → $17	Hold	Reiterates	$14 → $17	+1.19%	May 4, 2026
Vijay Kumar Evercore ISI	Evercore ISI	Buy Maintains $16 → $20	Buy	Maintains	$16 → $20	+19.05%	May 1, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

703.91M

from 655.35M

7.41%

from 655.35M

Revenue Next Year

774.02M

from 703.91M

9.96%

from 703.91M

EPS This Year

-1.59

from -1.22

EPS Next Year

-1.19

from -1.59

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	535.03M	537.84M	509.34M	605.22M	655.35M	703.91M
Revenue Growth	8.23%	0.53%	-5.30%	18.83%	8.28%	7.41%
Gross Profit	420.79M	423.58M	381.80M	469.05M	490.18M	530.28M
Gross Margin	78.65%	78.76%	74.96%	77.50%	74.80%	75.33%
Operating Income	-43.69M	-88.91M	-226.16M	-167.54M	-148.29M	-164.77M
Net Income	-58.35M	-92.53M	-207.04M	-168.63M	-136.23M	-183.30M
EPS	-	-	-	-	-1.22	-1.59
Free Cash Flow	104.89M	51.76M	-1.98M	8.60M	-37.98M	-31.55M
No. Analysts	-	-	-	-	-	7

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	710.0M
Avg	703.9M
Low	696.7M

Revenue Growth

Revenue Growth	2026	2027	2028
High	8.3%
Avg	7.4%
Low	6.3%

EPS Forecast

EPS	2026	2027	2028
High	-1.26
Avg	-1.59
Low	-1.78

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-